Carrier Frequency of Spinal Muscular Atrophy in a Large-scale Korean Population

Jong Eun Park, M.D.¹, Sun Ae Yun, M.T.², Eun Youn Roh, M.D.³, Jong Hyun Yoon, M.D.³, Sue Shin, M.D.³, and Chang-Seok Ki, M.D.⁴

¹Department of Laboratory Medicine, Hanyang University Guri Hospital, Hanyang University College of Medicine, Guri, Korea; ²Center for Clinical Medicine, Samsung Biomedical Research Institute, Samsung Medical Center, Seoul, Korea; ³Department of Laboratory Medicine, Boramae Hospital, Seoul National University College of Medicine, Seoul, Korea; ⁴GC Genome, Yongin, Korea

Spinal muscular atrophy (SMA) is an autosomal recessive disease characterized by progressive proximal muscle weakness and atrophy. Given the recent introduction of gene therapies, knowledge of the SMA carrier frequency in various populations has become important for developing screening programs for this disease. In total, 1,581 anonymous DNA samples from an umbilical cord blood bank were tested for SMN1 and SMN2 gene copies using a multiplex ligation-dependent probe amplification assay. Twenty-nine of the 1,581 newborns [1.83%; 95% confidence interval (CI), 1.25–2.66%] were SMA carriers with one copy of SMN1, and no homozygous SMN1 deletion was detected. The carrier frequency in this population was estimated to be 1,834 per 100,000 (95% CI, 1,254–2,659) or 1 in 55 (95% CI, 1/79–1/38). Our data indicate that SMA carriers are not uncommon in the Korean population and may serve as a reference for designing a population screening program in Korea.

Key Words: Korea, Spinal muscular atrophy, Carrier frequency, multiplex ligation-dependent probe amplification

Spinal muscular atrophy (SMA) is an autosomal recessive neurodegenerative disease characterized by progressive proximal muscle weakness and atrophy resulting from degeneration of the alpha motor neurons of the anterior horn of the spinal cord. SMA is phenotypically heterogeneous and is classified into four clinical subtypes based on the age of onset and motor function achieved [1]. Type I SMA presents marked weakness and developmental motor regression before the age of six months and usually results in death within two years. Type II SMA presents before the age of 18 months and is associated with difficulty in walking independently. Type III SMA presents after the age of 18 months and individuals walk independently with only supportive care and is seldom fatal. Type IV SMA presents in the second or third decade of life, with only minor muscle weak-
ness. The incidence of all types of SMA is estimated to be 1 in 10,000 live births globally [2].

SMA is caused by variants in SMN1 located on chromosome 5q13.2. Ninety-five percent of SMA patients have homozygous SMN1 deletions, whereas the remaining 5% have compound heterozygous SMN1 deletion and point variant. Most patients inherit variants from their parents; only approximately 2% of the affected patients have de-novo variants [1]. Although SMA patients lack a functional copy of SMN1, the nearly identical gene SMN2, located in the centromeric region of the same chromosome, produces a less functional protein through alternative splicing. The number of SMN2 copies varies within the general population and is inversely associated with disease severity [1].

In December 2016, the US Food and Drug Administration approved nusinersen (SPINRAZA™, Biogen, Cambridge, MA, USA), the first effective treatment for SMA (www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm534611.htm). Nusinersen is a modified antisense oligonucleotide that binds to a specific sequence, including exon 7 of SMN2 pre-messenger RNA, and increases the production of full-length SMN proteins. Nusinersen treatment in pre-symptomatic infants meaningfully increased the likelihood of survival and improved motor function [3]. Therefore, it is important to screen for SMA, carrier frequency of SMA, and SMN2 copy number at an early stage. Methods for SMA screening in newborns or adults have been actively studied and analyzed for cost-effectiveness [4, 5]. Although the SMN1 heterozygous deletion carrier frequency reportedly is between 2.00% (95% confidence interval [CI], 0.35–7.74%) and 2.15% (95% CI, 0.94–4.57%) in the Korean population [6, 7], no large-scale population studies have been performed. Therefore, we conducted a large-scale study to estimate the SMA carrier frequency in Korean newborns. Using the multiplex ligation-dependent probe amplification (MLPA) assay, we assessed the distribution of SMN1 and SMN2 copy numbers in umbilical cord blood samples from the newborns.

In total, 1,581 anonymous DNA samples obtained from a public umbilical cord blood bank (Seoul Metropolitan Government Cord Blood Bank, Seoul, Korea) were used. This study protocol was exempted from review by the Institutional Review Board (IRB) of Seoul National University Boramae Hospital, Seoul, Korea (07-2019-17) because the samples have been kept as a repository study under the approval of IRB. All samples were collected from mothers who provided informed consent for donation and research use of their cord blood. The MLPA analysis has been conducted since July 2019.

The MLPA assay was conducted using SALSA MLPA probe-mix P460-A1 SMA kits (MRC-Holland, Amsterdam, Netherlands), according to the manufacturer’s instructions (https://www.mlpa.com/WebForms/WebFormDBData.aspx?FileOID=_ImdLw-Ti-aZY). The PCR products were analyzed using an ABI PRISM 3100 ABI Genetic Analyzer (Applied Biosystems, Foster City, CA, USA). The data were analyzed using GeneMarker software, version 2.6 (Softgenetics, State College, PA, USA). Gene frequencies were calculated with VassarStats (http://vassarstats.net/), with 95% CI. The Hardy-Weinberg equilibrium was assessed by a professional web-based program (https://wpcalc.com/en/equilibrium-hardy-weinberg/).

The distribution of SMN1 and SMN2 copy numbers in the population is shown in Fig. 1. Of the 1,581 newborns, 29 (1.83%; 95% CI, 1.25–2.66%) were SMA carriers. Therefore, the carrier frequency in this population was estimated to be 1,834 per 100,000 (95% CI, 1,254–2,659) or 1 in 55 (95% CI, 1/79–1/38). Homozygous SMN1 deletion was not detected. One newborn was suspected as an SMN1 silent (2+0) carrier with two SMN1 copies on one chromosome 5 and deletion on the other [8]. We also assessed SMN2 copy numbers in this study population: 63.1% (N=998) had two copies of SMN2, 29.8% (N=471) had 0 or one copy, and 7.1% (N=112) had three or more copies. Among the SMA carriers, 24.1% (N=7) had 0 or one copy of SMN2, 58.6% (N=17) had two copies, and 17.2% (N=5) had three or more copies.

In this study, the SMN1 heterozygous deletion carrier frequency
was 1.83–1.90% (including silent carriers), which is similar to or lower than the frequencies reported in the previous Korean studies [6, 7]; however, in these studies, the CI was wide because of small sample numbers. Given the narrower CI in the current study, the SMA carrier frequency found here might be more accurate. Similar to findings in a previous study, the carrier frequency in our study was higher than that reported for other ethnicities, except Caucasians [9]. However, it was similar to or lower than that reported for the East Asian population (Table 1) [10–18]. The incidence of SMA caused by SMN1 homozygous deletion calculated using the Hardy–Weinberg equation was 1/11,815 in Koreans.

According to data from the Korean Statistical Information Service (http://kosis.kr; accessed on 17 May 2019), in 2017, the total population of South Korea was 51.42 million, with 357,771 births. Based on the carrier frequency in this study, the number of carriers was estimated to be 0.94 million in total, and 6,547 in newborns per year. Thus, the estimated incidence rate of SMA due to SMN1 deletion in Korea based on Hardy–Weinberg equilibrium is 30 cases per year.

With the development of drugs for the treatment of SMA, the need for newborn or carrier screening for the early diagnosis of SMA has become important. The US Secretary of Health and Human Services’ Advisory Committee on Heritable Disorders in Newborns and Children recommends the addition of SMA screening to default newborn screening programs (https://www.hrsa.gov/advisory-committees/heritable-disorders/rusp/index.html), and the American College of Obstetricians and Gynecologists recommend routine SMA carrier screening [19, 20]. Cost-effectiveness analyses of SMA screening have been reported. Little, et al. [4] reported that although universal prenatal screening for SMA is not cost-effective, screening of high-risk populations, such as those with a family history, may be. Zhang, et al. [5] reported that while SMA-only preconception carrier screening is not cost-effective, a combination screen for other conditions, such as cystic fibrosis and fragile X syndrome may prove to be and may prevent up to 30 SMA patients per million (all adults between the ages of 18 and 25 in the Australian health care system). Since the approval of nusinersen, there has been a lack of cost-effective analyses for newborn or carrier screening of SMA. Therefore, large-scale prospective newborn or carrier screening studies are needed for predicting the efficacy of nusinersen treatment.

Our study had some limitations. First, while 5% of SMA patients are known to have SMN1 missense variant, the MLPA assay is not a suitable method for detecting missense variants. Second, we experienced difficulties in identifying silent carrier phenotypes (e.g., SMN1 ‘2+0’ genotype) due to limitations of the MLPA method. Therefore, the SMA carrier frequency might be underestimated. This study also had various advantages. This is the first large-scale population study on the SMA carrier frequency in Koreans conducted using samples from a public umbilical cord blood bank. Further, because the CI used herein was narrower than that reported in previous studies [6, 7], the SMA carrier frequency and incidence predicted here might be more accurate. Finally, we evaluated the distribution of SMN2...
copy number in the general Korean population, which is important for predicting both the prognosis of patients with SMA and the efficacy of nusinersen treatment.

Our data indicate that carriers of \textit{SMN1} heterozygous deletion are not uncommon in the general Korean population. The carrier frequency was similar to or lower than that in the East Asian population and higher than that in other ethnicities. To our knowledge, this is the largest cohort study of \textit{SMN1} and \textit{SMN2} copy numbers in the Korean population to date, and our data are expected to serve as a reference for further investigation of SMA in the Korean population.

ACKNOWLEDGEMENTS

We thank all the mothers who donated their cord blood and the staff in the public cord blood bank.

AUTHOR CONTRIBUTIONS

CSK and SS conceived and designed the study, EYR and JHY performed umbilical cord blood data acquisition. Multiplex ligation-dependent probe amplification was performed by SAY and analyzed by JEP. JEP wrote the paper. All authors read and approved the final manuscript.

CONFLICTS OF INTEREST

No potential conflicts of interest relevant to this article were reported.

RESEARCH FUNDING

This study was supported by grants from the Brain Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Science, ICT (NRF-2017M3C7A1025363, NRF-2017M3C7A1025366).

ORCID

Jong Eun Park https://orcid.org/0000-0001-9131-6518
Sun Ae Yun https://orcid.org/0000-0002-8104-3496
Eun Youn Roh https://orcid.org/0000-0002-1787-7509
Jong Hyun Yoon https://orcid.org/0000-0002-1252-4739
Sue Shin https://orcid.org/0000-0003-4791-8671
Chang-Seok Ki https://orcid.org/0000-0001-7679-8731

REFERENCES

1. Prior TW, Leach ME, Finanger E. Spinal Muscular Atrophy. 2000 In: Adam MP, Ardinger HH, Pagon RA, et al., Eds. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2020. https://www.ncbi.nlm.nih.gov/books/NBK1352/ [Updated on Nov 2019].
2. Lunn MR and Wang CH. Spinal muscular atrophy. Lancet 2008;371: 2120-33.
3. Finkel RS, Mercuri E, Darras BT, Connolly AM, Kuntz NL, Kirschner J, et al. Nusinersen versus sham control in infantile-onset spinal muscular atrophy. N Engl J Med 2017;377:1723-32.
4. Little SE, Janakiraman V, Kaimal A, Musci T, Ecker J, Caughey AB. The cost-effectiveness of prenatal screening for spinal muscular atrophy. Am J Obstet Gynecol 2010;202:253.e1-7.
5. Zhang L, Bao Y, Riaz M, Tiller J, Liew D, Zhuang X, et al. Population genomic screening of all young adults in a health-care system: a cost-effectiveness analysis. Genet Med 2019;21:1958-68.
6. Yoon S, Lee CH, Lee KA. Determination of \textit{SMN1} and \textit{SMN2} copy numbers in a Korean population using multiplex ligation-dependent probe amplification. Korean J Lab Med 2010;30:93-6.
7. Lee TM, Kim SW, Lee KS, Jin HS, Koo SK, Jo I, et al. Quantitative analysis of \textit{SMN1} gene and estimation of \textit{SMN1} deletion carrier frequency in Korean population based on real-time PCR. J Korean Med Sci 2004; 19:870-3.
8. Luo M, Liu L, Peter I, Zhu J, Scott SA, Zhao G, et al. An Ashkenazi Jewish \textit{SMN1} haplotype specific to duplication alleles improves pan-ethnic carrier screening for spinal muscular atrophy. Genet Med 2014;16:149-56.
9. Verhaart IEC, Robertson A, Wilson UJ, Aartsma-Rus A, Cameron S, Jones CC, et al. Prevalence, incidence and carrier frequency of \textit{5q} linkage spinal muscular atrophy—a literature review. Orphanet J Rare Dis 2017;12: 124.
10. Chan V, Yip B, Yam I, Au P, Lin CK, Wong V, et al. Carrier incidence for spinal muscular atrophy in southern Chinese. J Neurol 2004;251:1089-93.
11. Sheng-Yuan Z, Xiong F, Chen YJ, Yan TZ, Zeng J, Li L, et al. Molecular characterization of \textit{SMN} copy number derived from carrier screening and from core families with SMA in a Chinese population. Eur J Hum Genet 2010;18:978-84.
12. Qu XX, Xiao B, Ji X, Jiang WT, Yang ZJ, Tao J. A pilot study on spinal muscular atrophy carrier screening in Shanghai region using real-time PCR. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 2013;30:1-4.
13. Gong B, Zhang L, Hou YP, Hu HY, Li HC, Tan MY, et al. Carrier screening for spinal muscular atrophy in 4719 pregnant women in Shanghai region. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 2013;30:670-2.
14. Tan J, Zhang X, Wang Y, Luo S, Yang F, Liu B, et al. Screening for spinal muscular atrophy mutation carriers among 4931 pregnant women from Luzhou region of Guangxi. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 2018; 35:467-70.
15. Huang CH, Chang YY, Chen CH, Kuo YS, Hwu WL, Gerdes T, et al. Copy number analysis of survival motor neuron genes by multiplex ligation-dependent probe amplification. Genet Med 2007;9:241-8.
16. Chen TH, Tzeng CC, Wang CC, Wu SM, Chang JG, Yang SN, et al. Identification of bidirectional gene conversion between \textit{SMN1} and \textit{SMN2} by simultaneous analysis of \textit{SMN} dosage and hybrid genes in a Chinese population. J Neurol Sci 2011;308:83-7.
17. Su YN, Hung CC, Lin SY, Chen FY, Chern JP, Tsai C, et al. Carrier screening for spinal muscular atrophy (SMA) in 107,611 pregnant women during the period 2005-2009: a prospective population-based cohort study.
18. Wang KC, Chang CC, Chang YF, Wang SH, Chiang CK, Tsai CP. Evaluation and characterization of a high-resolution melting analysis kit for rapid carrier-screening test of spinal muscular atrophy. J Neurogenet 2015;29:113-6.

19. Prior TW and Professional Practice and Guidelines Committee. Carrier screening for spinal muscular atrophy. Genet Med 2008;10:840-2.

20. Committee Opinion No. 691. Committee Opinion No. 691: Carrier screening for genetic conditions. Obstet Gynecol 2017;129:e41-55.